Stockreport

NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ... [Yahoo! Finance]

NRX Pharmaceuticals, Inc.  (NRXP) 
PDF Research and Development Expenses: Decreased from $3.3 million in Q3 2023 to $0.6 million in Q3 2024. General and Administrative Expenses: Slight decrease from $2.5 m [Read more]